Tainan City, Taiwan, Feb. 18, 2026 — Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology firm dedicated to the creation and commercialization of novel biomedical products for precision medicine and advanced diagnostics, has disclosed a reverse stock split of its issued and outstanding common stock at a 1-for-20 ratio (the “Reverse Split”). This action is scheduled to become effective at the opening of The Nasdaq Stock Market (“Nasdaq”) on February 20, 2026.
Pursuant to Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the Company’s outstanding voting power granted written consent for a reverse stock split of the issued and outstanding common stock. The approved ratio ranged from not less than 1-for-2 to not more than 1-for-100, with the board of directors holding sole discretion to determine the final ratio and timing. The board was also authorized to execute the reverse split at any subsequent time. Subsequently, on January 30, 2026, the board resolved to implement the reverse stock split at a specific ratio of 1-for-20.
The primary goal of this reverse split is to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), which mandates that issuers on The Nasdaq Capital Market maintain a minimum bid price of $1.00 per share.
Starting with the commencement of trading on February 20, 2026, the Company’s common stock will trade on a basis adjusted for the reverse split. It will continue to trade under the symbol “ADVB” but will be assigned a new CUSIP number: 00752P203.
Following the reverse split, every 20 shares of common stock with a par value of US$0.001 will automatically be consolidated into a single issued and outstanding share of common stock, retaining the same par value of US$0.001. This reverse split will impact all stockholders equally and will not modify any stockholder’s percentage ownership in the Company, barring minor adjustments resulting from the handling of fractional shares. Stockholders who hold their shares via a brokerage account are not required to take any action.
The Company will not issue any fractional shares in relation to the reverse split. Instead, any stockholder who would otherwise receive a fractional share will be entitled to receive one full share of common stock in the Company.
Upon the effectiveness of the share consolidation, the total number of the Company’s issued and outstanding common shares will decrease from 27,290,710 to approximately 1,364,536. The count of the Company’s authorized shares will remain the same.
About Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada corporation focused on specialized biomedical technologies for cancer detection and precision medicine.
Through its subsidiary in Taiwan, the Company has engineered a proprietary microfluidic platform that merges semiconductor and biotechnology to facilitate advanced circulating tumor cell (CTC) detection, enrichment, and analysis. The Company’s portfolio encompasses devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment. Regulatory clearances are currently underway in Taiwan, with strategies in place for future global expansion.
For more information, please visit: .
Forward‑Looking Statements
This press release includes statements that are forward-looking in nature. Such statements pertain to plans, objectives, goals, strategies, future events or performance, as well as underlying assumptions and other matters that are not historical facts. When the Company employs terms like “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions not strictly related to historical events, it is making forward-looking statements. These statements do not guarantee future performance and are subject to risks and uncertainties that could cause actual outcomes to differ materially from the expectations expressed. These statements are influenced by uncertainties and risks, including but not limited to market conditions and other factors outlined in documents filed with the United States Securities and Exchange Commission (the “SEC”). Consequently, investors are advised not to rely excessively on any forward-looking statements within this press release. Further details are available in the Company’s SEC filings, accessible at . The Company assumes no duty to publicly update these forward-looking statements to reflect new events or circumstances occurring after this date.
To reach the Company for further details:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email:
